Suzuken Co., Ltd. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018
November 05, 2017
Share
Suzuken Co., Ltd. announced consolidated earnings results for the six months ended September 30, 2017. For the period, the company reported net sales of ¥1,046,912 million against ¥1,055,174 million a year ago. Operating income was ¥6,246 million against ¥6,442 million a year ago. Ordinary income was ¥10,798 million against ¥10,972 million a year ago. Income before income taxes and non-controlling interests was ¥10,753 million against ¥10,164 million a year ago. Net income attributable to owners of the parent was ¥7,120 million or ¥74.80 basic per share against ¥6,534 million or ¥65.91 basic per share a year ago. Net cash provided by operating activities was ¥71,971 million against ¥16,349 million a year ago. Purchases of property and equipment were ¥2,919 million against ¥2,615 million a year ago. Acquisition of intangible fixed assets was ¥821 million against ¥1,567 million a year ago.
The company provided earnings guidance for the year ending March 31, 2018. For the year, the company expects net sales of ¥2,100,000 million, operating income of ¥10,300 million, ordinary income of ¥19,000 and net income attributable to owners of the parent of ¥12,100 million or ¥125.23 per share.
Suzuken Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in four business segments. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic drugs, and medical equipment and materials, among others. The Pharmaceutical Manufacturing segment manufactures pharmaceuticals and diagnostic drugs and others. The Insurance Pharmacy segment is engaged in dispensing operations based on prescriptions from medical institutions. The Medical-related Service and Others segment is engaged in the provision of manufacturer support services, such as the transportation of medicines and comprehensive support for the distribution of drugs for rare diseases; the nursing services; the manufacture of physiological examination equipment, such as electrocardiographic monitors and blood pressure monitors; as well as other services, such as the sale of medical books.
Suzuken Co., Ltd. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018